Happy to share our latest preprint. Thomas Kryza , Tashbib Khan and I developed 'substrate-biased' activity based probes to identify uPA as the master regulator of the oncogenic orphan transmembrane receptor, CDCP1. Check it out: researchsquare.com/article/rs-923…

Last week marked the kick-off of our 6th H2020 EU-funded project HARMLESS. The purpose of the project is to provide tools, guidance and decision support to ensure that the next generation nanomaterials will be harmless! #HARMLESS #IndustrialLeadership #SafebyDesign

Small but mighty! According to the latest H2020 country statistics, Misvik is ranked second among all Finnish life science, pharma and biotech companies in the number of participation to EC funded research and innovation projects! #IndustrialLeadership #H2020 #misvikbiology

Precision Toxicology consortium aims to protect human health from effects of harmful chemicals prnewswire.com/news-releases/…

Together with the NanoSafety Cluster nanocommons & NanoSolveIT H2020 EU Nanoinformatics Project offer a #webinar on the use of #linkeddata #resources #Online SPARQL Access to WikiPathways & AOP-Wiki Webinar" on 23rd March, 3:00 - 4:00 p.m. CET! Register now: attendee.gotowebinar.com/register/14291… nanocommons.eu

Interested in tailor made peptidyl diphenyl phosphonate warheads for analysis of proteolytic networks? Check out our latest collaborative study in Nature Chemical Biology: nature.com/articles/s4158…

The first version of the Cancer IO Ecosystem map is now online! See the map and check the key players in the Finnish IO Ecosystem. At this stage, the map includes all Cancer IO partners. Would you like to be involved - contact us! cancerio.org/en/ecosystem/ Business Finland

Even some of the most rare cancers can be caused by well known cancer susceptibility genes. Read our study on DNA repair targeting in an extreme rare cutaneous apocrine carcinoma associated with a Finnish founder mutation on PALB2. doi.org/10.18632/oncot… #rarecancer

Are you interested in the regulation of mesenchymal tumor phenotype in human cancers. Check out our latest work fresh off the press at Molecular Cell. doi.org/10.1016/j.molc…

Congratulations to Dr Sami Ventelä and colleagues for the great study! doi.org/10.1016/j.oral…

During these dark times one needs to find happiness from the small things. Well, today we celebrate our 8th anniversary! What a ride it’s been. Great science, great projects and most importantly great people and customers. Thank you for allowing us to work with you🥂🎉

Our clical study: Ex vivo determined cancer therapy #EVIDENT is now recruiting! clinicaltrials.gov/ct2/show/NCT05…

Do you want to join a team of scientists working towards precision toxicology? The University of Birmingham is looking for a Data Analyst in Bioinformatics and Biostatistics - deadline: 26th of May bham.taleo.net/careersection/…

CancerBio Summer School and Cancer IO present: ​ Special #Sebinar on "Hallmarks of Cancer: New Dimensions" by Professor Douglas Hanahan, the Swiss Institute for Experimental Cancer Research EPFL Welcome to join the Zoom event on 25 May at 13-14 EEST helsinki.zoom.us/j/64902684556?…✨

WEBINAR - 1 June: MEP Jytte Guteland (S&D) & PrecisionTox invite you to discuss "Better Chemical Safety for a Toxic-Free environment: Aiming for 100% REACH Compliance". >> RSVP to Ryan Hunter: [email protected] #NAMs #3Rs #EuropeanParliament #chemicals #environment

The dream-team working for a better environment gathered in Barcelona!

Huge congratulations to our newest Dr, Dr Patyra🎩🏆 Next three on the line😀 Go team Misvik! MisvikBiology

Last Call! Calling all early career researchers interested on nanomedicine and looking for a PhD position. Application period to Melomanes MSCA training network is closing! #PhD melomanes.eu/recruitment/

Target discovery using RNAi screening is still a valid approach. This time a novel DDR target FBXL12 for cancer therapy. Congratulations Sangfelt Lab! sciencedirect.com/science/articl…

Congratulations Ivaska Lab! What a great honor for us to contribute to this elegant piece of science! The cell microarray technologies still got it😃 Interested to develop your custom microarray platform? Contact us for more info! pnas.org/doi/10.1073/pn… Ivaska Lab PNASNews